Catalent (CTLT)
(Delayed Data from NYSE)
$59.40 USD
-0.31 (-0.52%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $59.37 -0.03 (-0.05%) 7:26 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 121 - 140 ( 219 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Inaugural Life Sciences & MedTech Conference: Key Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Science Tools: Hard and Soft Landings for COVID-19 Diagnostics and Vaccines
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Higher Growth at a Discount; Raise PT from $120 to $142
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Bioproduction: ''Guten Morgan Europe'' - Positive 2021 Industry Guides from Lonza and Sartorius
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Life Science Tools: DC Never Friendlier with Biden "American Rescue Plan"
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
D.C. Very Friendly with Biden "American Rescue Plan";
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Modeling COVID-19: Vaccine and Diagnostic Demand Outlook with Herd Immunity in 2021
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Assuming Co-Coverage and Upgrading to OW: ''Thermoesque'' Biologics Transformation
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department